HCA Healthcare stock edges lower as guidance cut and legal scrutiny weigh on valuation
Published on 09/07/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
HCA Healthcare Inc. stock (ISIN US40412C1018) is trading below its recent peak, with investors on September 7, 2026 weighing a profit guidance cut and legal scrutiny against a still-solid long-term track record and valuation that some see as supportive for new positions.
Guidance cut and fraud probe shape sentiment
According to Simply Wall St, HCA Healthcare recently reduced its 2026 profit guidance, citing a weaker payer mix that trimmed quarterly revenue by about USD 400 million, while a new fraud investigation by Pomerantz has added further scrutiny around the business as of early September 2026. The same analysis notes that HCA Healthcare shares delivered a negative 3.07% return over the last 7 days and a negative 2.02% return over the last 30 days, even though the 90 day share price return stands at a positive 12.09% and the three year total shareholder return at 51.53%, underlining the tension between short term caution and longer term strength.
The Simply Wall St narrative highlights that the most followed view currently places HCA Healthcare’s fair value at USD 458.67 per share compared with a recent closing price of about USD 405.00, implying that the stock is considered 11.7% undervalued by that framework as of September 6, 2026. For investors, this gap between fair value and the market price is central: the valuation thesis must be weighed against risks from payer mix, potential changes to Medicaid supplemental payments and ongoing legal questions.
Recent price level and market metrics
Market data compiled by MarketBeat show that HCA Healthcare stock opened at USD 404.95 on a recent trading day described as Monday, which corresponds to an early September 2026 session on the New York Stock Exchange. The same overview puts the company’s market capitalization at USD 87.67 billion based on that price, implying a price to earnings ratio of 13.56 and a price/earnings to growth (PEG) ratio of 1.33, figures that suggest the stock trades at a moderate multiple relative to its growth profile as of that session. Over the trailing 12 months, HCA Healthcare shares have traded between a low of USD 353.99 and a high of USD 556.52, meaning the early September price around USD 404.95 is roughly 14.4% above the 12 month low and about 27.3% below the 12 month high.
From a technical perspective, the same MarketBeat snapshot notes that HCA Healthcare carries a 50 day moving average of USD 403.35 and a 200 day moving average of USD 436.82, so the current price sits slightly above the shorter term trend but clearly below the longer term average. For investors, this configuration often signals that the stock has pulled back from higher levels but has not yet revisited deep lows, a pattern that fits with Simply Wall St’s observation that the recent decline of about 3.07% over seven days follows a stronger 12.09% gain over the last 90 days.
Earnings momentum and margins remain supportive
Fundamentally, HCA Healthcare last reported quarterly results for the period ending in the second quarter of 2026, with the figures reflected in the latest MarketBeat coverage. In that report, HCA Healthcare generated revenue of USD 20.23 billion in the quarter, up 8.7% year over year compared with the prior year’s quarterly revenue, underscoring that the business continues to grow its top line even as payer mix headwinds are discussed. Earnings per share (EPS) for the quarter came in at USD 7.59, beating the consensus estimate of USD 7.56 by USD 0.03 and improving from USD 6.84 in the same quarter a year earlier, indicating that profit per share increased by about 11.0% year on year.
The latest numbers also show that HCA Healthcare posted a net margin of 8.77% for the quarter and, despite reporting a negative return on equity figure of 244.79% due to capital structure specifics, continues to convert a significant portion of revenue into bottom line profit. On a full year basis, research analysts compiled by MarketBeat expect HCA Healthcare to deliver EPS of 29.42 for the current fiscal year, suggesting that the quarterly EPS of 7.59 in Q2 2026 represents roughly 25.8% of the full year forecast and is broadly in line with a steady earnings trajectory. For investors, the combination of mid single digit revenue growth, double digit EPS expansion and a single digit net margin supports the view that the core operations remain resilient even as management recalibrates guidance.
Dividend profile and capital allocation
In addition to earnings growth, HCA Healthcare offers a regular dividend stream that fits into a broader capital allocation strategy focused on returning cash to shareholders while funding expansion. MarketBeat reports that the company recently disclosed a quarterly dividend of USD 0.78 per share to be paid on September 30, 2026 to shareholders of record as of September 16, 2026, implying an annualized dividend of USD 3.12 if maintained. At the early September price near USD 404.95, this annualized dividend corresponds to a yield of about 0.8%, underlining that HCA Healthcare still prioritizes growth and reinvestment over high dividend payouts.
The payout ratio attached to this dividend is currently 10.45%, indicating that just over one tenth of earnings are returned to shareholders directly while the rest support investment in hospital capacity, technology and acquisitions. This aligns with Simply Wall St’s description of HCA Healthcare’s disciplined capital allocation strategy, which includes increasing facility and bed capacity and engaging in strategic acquisitions to drive long term value creation and revenue growth by meeting rising healthcare demand. For investors, a low payout ratio combined with ongoing buybacks and expansion provides optionality: cash can be deployed flexibly as conditions shift.
Analyst views and valuation debate
The analyst community remains broadly constructive on HCA Healthcare, though recent events have introduced more nuanced debates about risk and reward. According to MarketBeat, HCA Healthcare currently carries a consensus rating described as Moderate Buy, with fourteen analysts assigning a Buy rating, eight a Hold rating and one a Sell rating, and an average price target of USD 462.64 per share. Relative to the recent price around USD 404.95, this average target implies upside of about 14.3%, a figure that sits close to the 11.7% undervaluation highlighted by Simply Wall St’s fair value estimate of USD 458.67.
Individual houses have adjusted their views in recent months. Wells Fargo & Company raised its target price on HCA Healthcare shares from USD 369.00 to USD 381.00 in early August 2026 while maintaining an equal weight rating, signaling that the bank sees the stock fairly valued around those levels and prefers other opportunities for overweight exposure. Royal Bank of Canada reiterated an outperform rating with a price objective of USD 435.00 per share in late July 2026, while The Goldman Sachs Group cut its target from USD 558.00 to USD 485.00 and UBS Group lowered its target from USD 635.00 to USD 579.00, both still with buy ratings. These moves show that while the broad analyst stance remains positive, the upper end of target ranges has been recalibrated downward as guidance risks and legal questions emerged.
Key risks: payer mix and Medicaid exposure
The current risk narrative around HCA Healthcare is shaped by a combination of operational and regulatory factors that could weigh on future earnings if they intensify. Simply Wall St emphasizes that the guidance cut for 2026 was driven by a weaker payer mix, meaning a shift in the balance between commercial, Medicare and Medicaid reimbursements that reduced quarterly revenue by about USD 400 million. If payer mix continues to skew away from higher margin commercial contracts and toward lower reimbursement categories, revenue per equivalent admission and profit margins could come under further pressure.
Another highlighted risk is the potential for changes to Medicaid supplemental payments, which represent an important stream of support for hospital operators that serve a substantial share of low income patients. Any regulatory adjustments that reduce or restructure these payments could directly impact HCA Healthcare’s earnings sensitivity, especially in markets where Medicaid participation is high. Combined with the new Pomerantz fraud investigation referenced by Simply Wall St, which adds legal and reputational overhang, these factors form a counterweight to the undervaluation narrative and are central to the debate about how much of the guidance risk is already priced into HCA Healthcare stock.
Hospital operations and representative service offering
At the operating level, HCA Healthcare remains one of the largest for-profit hospital and healthcare facility operators in the United States, with a network of acute care hospitals, freestanding surgical centers, emergency centers and outpatient clinics distributed across multiple states. The company’s core activities include inpatient care, surgical services, emergency medicine, diagnostic imaging, laboratory testing and various outpatient and ambulatory care offerings, enabling it to capture a broad spectrum of patient needs from urgent interventions to planned procedures.
A representative pillar of HCA Healthcare’s model is its acute care hospital segment, where facilities typically combine emergency departments, operating rooms, intensive care units and specialty wards within large regional campuses. In practice, a typical HCA Healthcare hospital leverages scale to optimize bed utilization and staffing while feeding surgical centers and outpatient clinics with referrals, a structure that supports both revenue diversification and cost efficiency. For investors, the continued expansion of bed capacity and facility upgrades described in the Simply Wall St narrative is a key driver of long term revenue, particularly as demographic trends and rising healthcare utilization support sustained demand.
Stock remains tied to NYSE and S&P 500
HCA Healthcare stock is listed on the New York Stock Exchange with the ticker HCA and forms part of the S&P 500 index, anchoring it in the large cap US equity universe and making it a regular constituent in broad healthcare and benchmark funds. This positioning means that flows from index and sector funds can amplify moves around earnings reports, guidance updates and legal developments, as portfolio managers rebalance exposures to hospital services within the wider health care allocation.
As of the most recent MarketBeat snapshot in early September 2026, HCA Healthcare’s shares trade solely on the NYSE in USD, with no German Xetra or Tradegate listing evident in the week filtered search results, so retail investors in the DACH region typically access the stock via US venues or international brokers rather than local exchanges. In the hospital sector context, DACH investors may also compare HCA Healthcare to European peers such as listed German or Swiss hospital operators when evaluating relative valuation, though those names do not appear directly in the current search set.
HCA Healthcare stock price and investor perspective
Based on the MarketBeat data referenced above, HCA Healthcare stock recently traded around USD 404.95 on the New York Stock Exchange, with that price used as a representative level for the early September 2026 period. At this quotation, the shares stand noticeably below the 12 month high of USD 556.52 but remain above the 12 month low of USD 353.99, placing the current level in the lower half of the recent trading range and close to the 50 day moving average of USD 403.35. For investors, this positioning captures the present balance: guidance cuts and legal risks have compressed the valuation from earlier peaks, yet revenue growth, EPS expansion and a disciplined capital allocation policy still provide a fundamental underpinning for HCA Healthcare stock.
HCA Healthcare stock key data
- Company: HCA Healthcare Inc.
- ISIN: US40412C1018
- Ticker: HCA
- Trading venue: NYSE
- Price (as of September 6, 2026): 404.95 USD
- Market capitalization: 87.67 billion USD (as of September 6, 2026)
- Sector / Industry: Health Care / Hospital Services
- Index membership: S&P 500
